Online citations, reference lists, and bibliographies.
← Back to Search

Prognostic Factors For Patients With Newly Diagnosed Brain Metastasis From Breast Cancer.

C. Castaneda, R. Flores, Katerin Y Rojas, M. Castillo, K. Dolores-Cerna, C. Flores, Carolina Belmar-Lopez, Esperanza Milla, H. Gómez
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
AIM This retrospective study determined features associated with brain metastasis (BM) in women with breast cancer. PATIENTS & METHODS A total of 215 initially early breast cancer cases were included. We reviewed files and CT scan images of BM. RESULTS Median age was 47 years and most of our cases were stage III (58.6%), grade III (62.8%), ER negative (62.3%) and nonluminal (59.1%). Median survival after BM was 4 months. Nonluminal, extracranial disease, time to CNS shorter than 15 months, >three brain lesions and poor breast-graded prognostic assessment and recursive partitioning analysis scores were associated with shorter survival. Adding extracranial disease to breast-graded prognostic assessment score also predicted survival after BM. Radiation response was assessed in 57 patients and response tended to be associated with nonluminal phenotype but not with survival. CONCLUSION Factors associated with both initial tumor and clinical features at BM time are associated with shorter survival in our Latinas population.
This paper references
10.1186/1471-2407-7-203
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
B. Keam (2007)
10.1097/01.pas.0000213306.05811.b9
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR
D. Hicks (2006)
10.1002/cncr.22041
Primary breast cancer phenotypes associated with propensity for central nervous system metastases
Y. Tham (2006)
10.1200/JCO.2011.38.0527
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.
P. Sperduto (2012)
10.1016/J.CLON.2004.03.012
Brain metastases from breast cancer: identification of a high-risk group.
A. Evans (2004)
10.1016/S0360-3016(98)00198-9
Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases.
O. Agboola (1998)
Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer reSearch article overexpressing metastatic breast cancer
Z Gabos
10.1016/S0360-3016(96)00619-0
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.
L. Gaspar (1997)
10.1158/0008-5472.SABCS11-P2-14-09
P2-14-09: Comparison between Spanish and Peruvian Patients with Early Breast Cancer.
Carlos Castañeda (2011)
10.1093/ANNONC/MDH432
Risk factors for brain relapse in patients with metastatic breast cancer.
K. Slimane (2004)
10.1016/S0360-3016(02)02967-X
Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study.
A. S. Mahmoud-Ahmed (2002)
10.1200/JCO.2012.43.4134
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.
A. Prat (2013)
10.1016/J.BREAST.2005.04.017
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
H. Stemmler (2006)
10.1038/nature08021
Genes that mediate breast cancer metastasis to the brain
P. Bos (2009)
subtype , age , and race among patients with breast cancer brain metastases
PD Bos (2011)
10.1148/rg.317115050
Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0.
H. Chalian (2011)
10.1200/JCO.2000.18.10.2059
Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189.
J. Simpson (2000)
10.3816/CBC.2010.n.038
Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database.
Carlos S. Vallejos (2010)
10.1016/S0360-3016(00)00547-2
Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases.
L. Gaspar (2000)
10.1093/ANNONC/MDL064
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).
B. Pestalozzi (2006)
10.4048/JBC.2010.13.2.160
Clinical Outcomes in Patients with Triple-negative Breast Cancer and Brain Metastases
Hyuk-chan Kwon (2010)
Prognostic value of histologic grade and proliferative activity in axillary node - positive breast cancer : results from the Eastern Cooperative Oncology Group Companion Study , EST 4189
A Prat (2000)
10.1016/j.ijrobp.2009.06.030
The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
A. Niwińska (2010)
Pathology and genetics of tumours of the nervous system.
P. Kleihues (2000)
phenotypes associated with propensity for central nervous system metastases
HJ Stemmler (2006)
10.1200/JCO.2006.07.0250
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
10.1002/cncr.25746
The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases
C. Anders (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar